CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE

FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2025

(With Summarized Totals for the Year Ended December 31, 2024)

RitzHolman CPAs

CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE

TABLE OF CONTENTS

RitzHolman CPAs

Independent Auditor's Report

Board of Directors
Childhood Arthritis and Rheumatology Research Alliance

Opinion

We have audited the accompanying financial statements of Childhood Arthritis and Rheumatology Research Alliance (a nonprofit organization) which comprise the statement of financial position as of December 31, 2025, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Childhood Arthritis and Rheumatology Research Alliance as of December 31, 2025, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Childhood Arthritis and Rheumatology Research Alliance and to meet other ethical responsibilities in accordance with the ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Childhood Arthritis and Rheumatology Research Alliance's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Ritz Holman LLP
Serving businesses, nonprofits, individuals and trusts.

330 E. Kilbourn Ave., Suite 222 t. 414.271.1451
Milwaukee, WI 53202 f. 414.271.7464
ritzholman.com

Board of Directors
Childhood Arthritis and Rheumatology Research Alliance

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Childhood Arthritis and Rheumatology Research Alliance's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Childhood Arthritis and Rheumatology Research Alliance's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited Childhood Arthritis and Rheumatology Research Alliance's December 31, 2024, financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated June 23, 2025. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2024, is consistent, in all material respects, with the audited financial statements from which it has been derived.

Ritz Holman LLP

RITZ HOLMAN LLP
Certified Public Accountants

Milwaukee, Wisconsin
July 8, 2026

CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE
STATEMENT OF FINANCIAL POSITION
DECEMBER 31, 2025
(With Summarized Totals for December 31, 2024)

ASSETS

	2025	2024
CURRENT ASSETS		
Cash and Cash Equivalents	$ 1,845,966	$ 14,989,247
Accounts Receivable	2,164,820	2,259,279
Investments	11,282,255	---
Prepaid Expenses	22,865	72,796
Biobank Supplies	8,255	4,985
Total Current Assets	$ 15,324,161	$ 17,326,307
OTHER ASSETS		
Intangible Asset In Progress	$ 5,808	$ ---
Intangible Assets	135,168	135,168
Less: Accumulated Amortization	(92,326)	(67,836)
Total Other Assets	$ 48,650	$ 67,332
TOTAL ASSETS	$ 15,372,811	$ 17,393,639

LIABILITIES AND NET ASSETS

	2025	2024
CURRENT LIABILITIES		
Accounts Payable	$ 2,297,245	$ 2,075,342
Accrued Liabilities	117,938	92,734
Current Portion of Grants Payable	1,440,172	1,434,694
Current Portion of Deferred Revenue	760,645	1,014,627
Total Current Liabilities	$ 4,616,000	$ 4,617,397
LONG-TERM LIABILITIES		
Deferred Revenue	$ 914,494	$ 1,633,722
Less: Current Portion of Deferred Revenue	(760,645)	(1,014,627)
Grants Payable	1,966,507	1,893,351
Less: Current Portion of Grants Payable	(1,440,172)	(1,434,694)
Total Long-Term Liabilities	$ 680,184	$ 1,077,752
Total Liabilities	$ 5,296,184	$ 5,695,149
NET ASSETS		
Without Donor Restrictions	$ 10,076,627	$ 11,698,490
Total Net Assets	$ 10,076,627	$ 11,698,490
TOTAL LIABILITIES AND NET ASSETS	$ 15,372,811	$ 17,393,639

The accompanying notes are an integral part of these financial statements.

CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE
STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED DECEMBER 31, 2025
(With Summarized Totals for the Year Ended December 31, 2024)

	Without Donor Restrictions 2025	Without Donor Restrictions 2024
REVENUE		
General Revenue		
Membership Dues	$ 75,720	$ 57,145
Corporate Council Membership Dues	89,295	18,204
Investment Income	870,827	676,150
Donations	281,334	193,241
Registration	2,000	400
Sponsorships	70,000	50,000
In-Kind Revenue	442,245	486,404
Total General Revenue	$ 1,831,421	$ 1,481,544
Grant and Contract Revenue		
Grant Revenue	$ 747,146	$ 632,603
Contract Revenue	7,287,488	7,963,974
Total Grant and Contract Revenue	$ 8,034,634	$ 8,596,577
Total Revenue	$ 9,866,055	$ 10,078,121
EXPENSES		
Program Services	$ 9,810,634	$ 9,554,329
Management and General	1,322,024	1,228,724
Fundraising	355,260	294,912
Total Expenses	$ 11,487,918	$ 11,077,965
CHANGE IN NET ASSETS	$ (1,621,863)	$ (999,844)
Net Assets, Beginning of Year	11,698,490	12,698,334
NET ASSETS, END OF YEAR	$ 10,076,627	$ 11,698,490

The accompanying notes are an integral part of these financial statements.

CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE
STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2025
(With Summarized Totals for the Year Ended December 31, 2024)

	Program Services	Management and General	Fundraising	2025 Total	2024 Total
Advertising/Marketing	$ ---	$ 12,741	$ ---	$ 12,741	$ 7,507
Amortization Expense	---	24,490	---	24,490	24,490
Audio Visual and Equipment	71,472	---	---	71,472	8,560
Bank and Credit Card Fees	---	15,476	---	15,476	8,077
Bio Sample	255,905	---	---	255,905	386,626
Dues/Subscriptions	---	3,882	---	3,882	3,805
Employee Recruitment and Retention	---	3,460	---	3,460	61
Executive Committee Management	128,514	42,838	---	171,352	204,376
Food and Beverage - Annual Meeting	184,233	---	---	184,233	1,323
Conferences and Meetings	16,919	---	38,817	55,736	50,405
Grant Support to Others	1,975,093	---	---	1,975,093	1,917,390
Informatics Contracts	120,584	---	---	120,584	421,903
Insurance	---	33,596	---	33,596	34,503
Manuscripts	68,136	---	---	68,136	85,400
Member Travel	105,516	---	---	105,516	190
Miscellaneous Expenses	---	17,960	---	17,960	9,273
Office Supplies	---	2,211	---	2,211	2,009
Postage and Shipping	---	1,911	---	1,911	1,276
Printing and Copying	7,782	994	---	8,776	7,697
Professional Fees	510,686	263,189	171,689	945,564	700,007
Registry Operations	3,486,559	---	---	3,486,559	3,314,635
Salary Support	877,270	571,093	118,290	1,566,653	1,570,438
Payroll Taxes	69,730	45,394	9,402	124,526	116,113
Employee Benefits	126,532	82,371	17,062	225,965	240,613
Site Payments	1,369,305	---	---	1,369,305	1,320,115
Software	---	120,610	---	120,610	114,519
Staff Travel	13,850	15,011	---	28,861	18,604
Staff Training and Development	---	3,046	---	3,046	238
Website	---	61,751	---	61,751	67,945
Work Effort - Contracts	416,842	---	---	416,842	395,818
Work Effort - Mentorship	5,706	---	---	5,706	44,049
TOTALS	$ 9,810,634	$ 1,322,024	$ 355,260	$ 11,487,918	$ 11,077,965

The accompanying notes are an integral part of these financial statements.

CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED DECEMBER 31, 2025
(With Summarized Totals for the Year Ended December 31, 2024)

	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in Net Assets	$ (1,621,863)	$ (999,844)
Adjustments to Reconcile Change in Net Assets to Net Cash Provided by Operating Activities		
Unrealized (Gain) Loss on Investments	(371,536)	---
Amortization Expense	24,490	24,490
(Increase) Decrease in Accounts Receivable	94,459	344,760
(Increase) Decrease in Prepaid Expenses	49,931	(49,691)
(Increase) Decrease in Biobank Supplies	(3,270)	(3,006)
Increase (Decrease) in Accounts Payable	221,903	725,476
Increase (Decrease) in Grants Payable	73,156	468,490
Increase (Decrease) in Accrued Liabilities	25,204	23,300
Increase (Decrease) in Deferred Revenue	(719,228)	(230,802)
Net Cash (Used) Provided by Operating Activities	$ (2,226,754)	$ 303,173
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of Investments	$ (13,910,719)	$ ---
Sale of Investments	3,000,000	---
Purchase of Intangible Assets	(5,808)	---
Net Cash Used by Investing Activities	$ (10,916,527)	$ ---
Net (Decrease) Increase in Cash and Cash Equivalents	$ (13,143,281)	$ 303,173
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	14,989,247	14,686,074
CASH AND CASH EQUIVALENTS AT END OF YEAR	$ 1,845,966	$ 14,989,247

The accompanying notes are an integral part of these financial statements.

CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE

NOTES TO THE FINANCIAL STATEMENTS

DECEMBER 31, 2025

NOTE A - Summary of Significant Accounting Policies

Organization
Childhood Arthritis and Rheumatology Research Alliance's (the "Organization") purpose is to conduct collaborative research to prevent, treat and cure pediatric rheumatic diseases.

Accounting Method
The financial statements of the Organization have been prepared on the accrual basis of accounting.

Basis of Presentation
The Organization reports information regarding its financial position and activities according to two classes of net assets: net assets without donor restrictions and net assets with donor restrictions.

Cash and Cash Equivalents
For purposes of the statement of cash flows, cash and cash equivalents include all highly liquid debt instruments with original maturities of three months or less when purchased.

Accounts Receivable and Credit Losses
Accounts receivable on trade and other receivables are stated at unpaid balances, less an allowance for credit losses. The expected credit losses are updated by management at each reporting date to reflect changes in credit risk since the financial instrument was initially recognized. The expected credit losses on trade or other receivables are estimated based on historical credit loss experience, aging analysis, and management's assessment of current conditions and reasonable and supportable expectations of future conditions. The Organization assesses collectability by pooling receivables where similar characteristics exist and evaluates receivables individually when specific customer balances no longer share those risk characteristics and are considered at risk or uncollectible. Accounts receivable balances are charged off against the allowance for credit losses after recovery efforts have ceased. The expense associated with the allowance for expected credit losses is recognized in bad debts expense. As of December 31, 2025, accounts receivable are expected to be collected in full; therefore, no allowance for credit losses has been recorded.

Fixed Assets
Fixed assets are recorded at cost. All tangible personal property with a useful life of more than one year and a unit acquisition cost of $10,000 or more will be capitalized and depreciated over its useful life using the straight-line method of depreciation.

Intangible Assets
The Organization capitalizes all expenditures for intangible assets that have a useful life greater than one year. The intangible assets are recorded at cost and amortized over the estimated useful lives of the respective assets on a straight-line basis.

NOTE A - Summary of Significant Accounting Policies (continued)

Contributions and Grant Revenue

Contributions received and unconditional promises to give are measured at their fair values and are reported as increases in net assets. Contributions are considered available for the Organization's general programs unless specifically restricted by the donor. Contributions received with restrictions that are met in the same reporting period are reported as revenue without donor restrictions and increase net assets without donor restrictions. Conditional promises to give are not recognized until they become unconditional. A conditional contribution is one that has both a barrier that must be overcome and an agreement requiring advance payment to be returned or future payment not to be obligated when the barrier is not overcome. Amounts received for which the donor has limited the use of the asset or designated the gift as support for future periods are considered restricted support and included in net assets with donor restrictions. When a donor restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. When the restriction on a contribution is met in the same reporting period as the contribution is received, the contribution is reported in net assets without donor restrictions.

Net assets restricted for acquisition of building or equipment are reported as net assets with donor restrictions until the specified asset is placed in service when the net assets are released to net assets without donor restrictions.

When a donor requires the investment of a contribution and restricts the use of investment income, the investment income is reported as net assets with donor restrictions until appropriated for the designated time or use when the net assets are released to net assets without donor restrictions.

Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift. Donated services are recognized as contributions if the services create or enhance nonfinancial assets or the services require specialized skills, are performed by people with those skills, and would otherwise be purchased by the Organization. Accordingly, the value of contributed time that does not meet these requirements has not been determined and is not reflected in the accompanying financial statements.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Functional Expenses

The Organization allocates costs directly to program and management when appropriate. Certain expenses are attributable to one or more programs or supporting functions of the Organization. Those expenses are allocated based on estimates of time and effort.

NOTE B - Comparative Financial Information

The financial information shown for 2024 in the accompanying financial statements is included to provide a basis for comparison with 2025. The comparative information is summarized by total only, not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity to generally accepted accounting principles. Accordingly, such information should be read in conjunction with the Organization's financial statements for the year ended December 31, 2024, from which the summarized information was derived.

NOTE C - Concentration of Risk

The Organization maintains its cash balances at several financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. At December 31, 2025, the Organization's uninsured cash balances total $1,585,075.

One source of the Organization's accounts receivable is 64% of the balance. Of the accounts payable balance, 66% is for one vendor. Four sources of grants payable represent 50% of the grants payable balance.

NOTE D - Liquidity

Financial assets available for use are those assets considered liquid and expected they could be readily convertible to cash within one year of the statement of financial position date to meet cash needs for general expenditures and to pay obligations as they become due. Financial assets that are restricted by contract or the donor are considered unavailable for general expenditures and excluded from financial assets available for use. The Organization has credit cards with available credit of $100,000, of which $-0- was in use as of December 31, 2025. The Organization monitors liquidity by tracking financial ratios and cash flow to determine their ability to meet short-term obligations.

Financial assets available for use consist of the following as of December 31, 2025:

Description	Amount
Cash and Cash Equivalents	$ 1,845,966
Accounts Receivable	2,164,820
Investments	11,282,255
Available for Use	$15,293,041

NOTE E - Accounts Receivable

Accounts receivable consists of $2,164,820 related to contract revenue as of December 31, 2025. All amounts are expected to be collected in 2026.

NOTE F - Fair Value Measurements

The Organization has adopted the Financial Accounting Standards Board guidance on fair value measurements. A three-tier hierarchy is used to maximize the use of observable market data inputs and minimize the use of unobservable inputs and to establish classification of fair value measurements for disclosure purposes. Financial assets valued using Level 1 inputs are based on unadjusted quoted market prices within active markets. Financial assets valued using Level 2 inputs are based primarily on quoted prices for similar assets in active or inactive markets. Financial assets valued using Level 3 inputs are based primarily on valuation models with significant unobservable pricing inputs and which result in the use of management estimates.

The following table sets forth by level, within the fair value hierarchy, the Organization's assets at fair value as of December 31, 2025:

Investment Category	Fair Value	Quoted Prices In Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Equities	$ 5,413,615	$ 5,413,615	$ ---	$ ---
Fixed Income	3,611,421	3,611,421	---	---
Subtotal	$ 9,025,036	$ 9,025,036	$ ---	$ ---
Cash and Cash Equivalents	2,257,219			
Total Investments	$11,282,255			

NOTE G - Intangible Assets

Intangible assets presented on the statement of financial position as of December 31, 2025, consists of the following:

Amortized Asset	Gross Value	Accumulated Amortization	Residual Value	Life
Website	$ 12,719	$12,719	$ ---	5 years
Website Redesign	96,399	59,446	36,953	5 years
Mobile App	25,000	19,583	5,417	5 years
App Trademark	1,050	578	472	5 years
Total	$135,168	$92,326	$42,842	

Estimated amortization expense for future years are as follows:

For the Year Ending December 31,	Amount
2026	$24,490
2027	18,300
2028	52
Total	$42,842

Residual value of the startup costs of $5,808 for the asset in progress are excluded from the schedule above and will be capitalized subsequent to the asset being placed in service.

NOTE H - Grants Payable

The Organization has $1,966,507 of grants payable as of December 31, 2025, which is related to the contracts signed with various corporations.

Future grants payable payments are as follows:

For the Year Ending December 31,	Amount
2026	$1,440,172
2027	526,335
Total	$1,966,507

NOTE I - Deferred Revenue

Deferred revenue consists of the following amounts as of December 31, 2025:

Source	Amount
Grant and Contract Revenue	$746,283
Membership Dues	5,195
Corporate Council Membership Dues	9,167
Total Current Portion of Deferred Revenue	$760,645

Source	Amount
Contract Revenue	$153,849
Total Non-Current Portion of Deferred Revenue	$153,849
Total Deferred Revenue	$914,494

Future recognition of deferred revenue is expected as follows:

For the Year Ending December 31,	Amount
2026	$760,645
2027	153,849
Total Deferred Revenue	$914,494

NOTE J - Revenue from Contracts with Customers

Sponsorship

The Organization hosts an annual convention and various conferences and meetings for professionals in the industry. Registration fees for these events are billed to the participant at the time of registration. The event revenue is reported at the amount that reflects the consideration to which the Organization expects to be entitled in exchange for providing the registrant access to the event and event materials. Revenue from these events are recognized at the point in time the event is held and the Organization's performance obligation to hold the event is completed.

Beginning Deferred Convention Revenue	$ 5,000
Revenue Recognized from Prior Year Deferred	(5,000)
New Convention Revenue	65,000
Revenue Recognized on Conventions	(65,000)
Ending Deferred Convention Revenue	$ ---

NOTE J - Revenue from Contracts with Customers (continued)

Membership Dues

The Organization offers a membership which provides members with a package of benefits. In general, membership in the Organization provides the member with the ability to apply for CARRA grants and travel awards, have access to the CARRA members only collaboration site, receive travel support to attend the annual scientific meeting, and opportunities to engage with CARRA research committees. The member dues revenue is reported at the amount that reflects the consideration to which the Organization expects to be entitled in exchange for providing the member access to the requisite member benefits. The Organization's membership dues are billed annually in advance of the membership year which runs from January 1 to December 31 and are recorded as a contract liability (deferred membership dues) until earned. These revenues are recognized over a period of time which corresponds with the membership year.

Beginning Deferred Membership Dues	$ 41,227
Revenue Recognized from Prior Year Deferred	(41,227)
New Memberships Issued	138,150
Revenue Recognized on New Membership	(123,788)
Ending Deferred Membership Dues	$ 14,362

Contract Service Fee Revenue

Contract service fee revenue is reported at the amount that reflects the consideration to which the Organization expects to be entitled in exchange for contract services. The Organization bills the customer for fees after the services are completed. Revenue from the services are recognized at the point in time the service is provided and the Organization's performance obligation to provide the service is completed. The Organization signed multi-year contracts relating to future services. As of December 31, 2025, the Organization has available contract funds of $5,981,153, which are available through 2027. The Organization had receivables of $2,164,820 and $2,259,279 for the years ended December 31, 2025 and 2024, respectively.

Beginning Deferred Contract Service Fees	$ 1,587,496
Revenue Recognized from Prior Year Deferred	(1,587,496)
New Contract Service Fee Revenue	6,600,124
Revenue Recognized on Contract Service Fees	(5,699,992)
Ending Deferred Contract Service Fees	$ 900,132

NOTE K - Conditional Contributions

The Organization has contracts with governmental agencies which include specific use stipulations requiring funds be used only on qualifying expenses determined by the grant contract and allowable cost policies. The Organization will not receive the grant funds unless spent on the required activity and within the allowable cost guidance. As of December 31, 2025, the Organization has grant funds of $590,190 available for its programs through September 30, 2026.

NOTE L - In-Kind Contributions

The Organization received total in-kind services of $442,244. Services were utilized during the year and value was based on fair market value.

Type of Service	Amount
Legal	$427,244
ERP Implementation	15,000
Total	$442,244

NOTE M - Retirement Plan

The Organization maintains a 401(k) retirement plan covering employees who worked at least six months. The contributions are immediately vested upon employee eligibility. The Organization made contributions of 5% of eligible employees' monthly gross wages for January through December of 2025. Total retirement expense for the year ended December 31, 2025, was $63,713.

NOTE N - Income Taxes

The Organization is exempt from income tax under Section 501(c)(3) of Internal Revenue Code and is classified as other than a private foundation. Management has reviewed all tax positions recognized in previously filed tax returns and those expected to be taken in future tax returns. As of December 31, 2025, the Organization had no amounts related to unrecognized income tax benefits and no amounts related to accrued interest and penalties. The Organization does not anticipate any significant changes to unrecognized income tax benefits over the next year.

NOTE O - Subsequent Events

The Organization has evaluated events and transactions occurring after December 31, 2025, the date of the most recent statement of financial position, through the date financial statements are available to be issued, July 8, 2026, for possible adjustment to the financial statements or disclosure and determined that no subsequent events need to be disclosed.